How Trump Blew Up Northwestern's Business Model
In April, Northwestern University cardiologist Dr. Rod Passman learned the National Institutes of Health had abruptly halted funding for a $37 million trial testing a new way to treat dangerous heart arrhythmias, with about 1,500 patients already enrolled.
It was part of a universitywide funding freeze that threatened to stall hundreds of projects, including clinical trials with patients on lifesaving medication.Through the spring, Northwestern used university money to pay bills previously covered by NIH grants, spending tens of millions of dollars monthly to keep labs and trials running without a break. Researchers and administrators now worry this stopgap can't last.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Eating this fatty snack every day can help you sleep better — scientists were surprised
Those delicious darlings on every brunch menu may be more than just a creamy topping. It turns out this popular green fruit — yes, it's a fruit — may just be the key to restful slumber, according to a new study in the Journal of the American Heart Association. Researchers tracked 969 adults aged 25 and over who had abdominal obesity, which is characterized as a waistline that is 35 inches or more for women and 40 inches or more for men. For 26 weeks, half of the group ate one large Hass avocado per day while the other half continued their usual diet, which typically involved consuming less than two avocados per month. As expected, the avocado-eating group saw marked improvements in their blood lipids — fatty substances like triglycerides and cholesterol — and overall diet. But what caught researchers off guard was the fact that this trendy toast-topper also led to better sleep. The researchers noted that avocado's impact on sleep may be due to its powerhouse blend of nutrients, as it's 'rich in monounsaturated fatty acids, dietary fiber, potassium, folate, vitamin K, copper and pantothenic acid.' It also came as a surprise that avocado consumption was not associated with improved cardiovascular health, which was actually the original purpose of the study. The researchers noted that avocados could benefit slumber as part of a balanced, healthy diet and should not be treated as a solitary sleep aid. 'Sleep is emerging as a key lifestyle factor in heart health, and this study invites us to consider how nutrition — and foods like avocado — can play a role in improving it,' said Dr. Kristina Petersen, study author and associate professor of nutritional sciences at Penn State University. 'Cardiovascular health is influenced by many factors, and while no single food is a silver bullet, some — like avocados — offer a range of nutrients that support multiple aspects of heart health. This is an encouraging step in expanding the science around avocados and the potential benefits of consumption.' Other factors that can improve your sleep include cutting down on caffeine, curbing alcohol intake, kicking a smoking habit, exercising and limiting screen time before bed. This isn't the first time the versatile superfood has made headlines for unexpected benefits. Previous research suggests avocados may reduce 'bad' cholesterol and help with belly fat in women, thanks to their healthy fats and high fiber content. A 2024 study suggests that eating a small amount of avocado every day may lower a woman's risk for Type 2 diabetes. Just make sure not to overdo it. Experts generally recommend eating no more than one avocado per day to avoid unwanted weight gain.
Yahoo
an hour ago
- Yahoo
Jack L. Marcus, Inc. Issues Notice of Privacy Breach Affecting Wisconsin Department of Corrections Population
MILWAUKEE, June 15, 2025 (GLOBE NEWSWIRE) -- Jack L. Marcus, Inc. is providing notice of a privacy breach involving the protected health information (PHI) of individuals in the care of the Wisconsin Department of Corrections (DOC). The breach involved the unintentional disclosure of the names of six DOC treatment facilities through Jack L. Marcus's public ordering website. Between August 15, 2024, and May 16, 2025, individuals placing orders for persons in DOC care (PIOCs) were able to view the name of the treatment facility—though not the address—of certain PIOCs during the checkout process. The breach was discovered on May 15, 2025, and the issue was corrected within 24 hours. The breach affected 705 individuals. No medical records, financial data, Social Security numbers, or other sensitive health information was involved—only the name of the facility where the individual was housed. Jack L. Marcus, Inc. has taken immediate corrective steps, including updating its website to ensure facility names are no longer displayed, conducting a full internal review, and enhancing its privacy and compliance training. Letters have been mailed to all affected individuals using addresses provided by the Wisconsin Department of Corrections. Jack L. Marcus has also notified the U.S. Department of Health and Human Services (HHS), as required under the Health Insurance Portability and Accountability Act (HIPAA). For More Information:Individuals with questions can contact: Eric LutzenVice President of OperationsJack L. Marcus, Inc.5300 W. Fond du Lac AvenueMilwaukee, WI 53216Phone: (414) 438-4999Email: eric@ Jack L. Marcus, Inc. deeply regrets this incident and is committed to safeguarding the privacy of all individuals it in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. ( ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, in the first-line treatment of advanced, recurrent, or metastatic cervical cancer. The data was featured as an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The subgroup analysis demonstrated that cadonilimab treatment significantly improved progression-free survival (PFS) and overall survival (OS) across different patient subgroups, including: levels of PD-L1 expression, prior treatment with concurrent chemoradiotherapy (CCRT), bevacizumab use, and age of the patients (≥65, <65). These results further demonstrate the clinical value and the global women's health impact of cadonilimab in advancing thetreatment standart for advanced cervical cancer. The results of the COMPASSION-16 study were previously published in The Lancet and presented at the 2024 International Gynecologic Cancer Society (IGCS) Global Meeting. The Lancet publication and the IGCS presentation disclosed that cadonilimab, in combination with platinum-based chemotherapy (with or without bevacizumab), significantly extended survival in both PD-L1-positive and PD-L1-negative patient populations (mOS HR 0.64, P=0.0011), and reduced the risk of disease progression and death (mPFS HR 0.62, P<0.0001). At the 2025 ASCO annual meeting, the study's principal investigator, Professor Xiaohua Wu from the Fudan University Shanghai Cancer Center, presented the subgroup analysis findings from the COMPASSION-16 study, with data cut-off as of April 30, 2024. Key Findings: Significant Reduction in Mortality Risk Across All Patient Subgroups, Regardless of PD-L1 Expression: In the CPS<1 group, mPFS was 12 months in the cadonilimab arm vs. 8.2 months in the control arm (HR=0.65), and mOS was not reached in the cadonilimab arm vs. 25.3 months in the control arm (HR=0.77). In the CPS≥1 group, mPFS was 14.7 months in the cadonilimab arm vs. 8.3 months in the control arm (HR=0.62), and mOS was not reached in the cadonilimab arm vs. 22.7 months in the control arm (HR=0.69). In the CPS≥10 group, mPFS was 17.1 months in the cadonilimab arm vs. 8.1 months in the control arm (HR=0.54), and mOS was not reached in the cadonimab arm vs. 29 months in the control arm (HR=0.68). Clinical Benefit in PFS and OS Regardless of Prior CCRT Treatment: In patients previously treated with CCRT, mPFS was 16.1 months in the cadonilimab arm vs. 7.9 months in the control arm (HR=0.55), and mOS was not reached in the cadonilimab arm vs. 22.8 months in the control arm (HR=0.54). Clinical Benefit in PFS and OS Regardless of Bevacizumab Use: In real-world settings, approximately 40% of patients are considered unsuitable for bevacizumab due to underlying conditions or bleeding/perforation risks. Cadonilimab demonstrated clinically meaningful improvements in both PFS and OS, whether or not bevacizumab was included in the treatment. In the bevacizumab-naive groups, mPFS was 11.7 months in the cadonilimab arm vs. 6.7 months in the control arm (HR=0.44), and mOS was 28.2 months in the cadonilimab arm vs. 15.1 months in the control arm (HR=0.5). Improvement in PFS and OS Across Age Subgroups, with Greater Efficacy in Patients ≥65 Years: In patients < 65 years, mPFS was 13.5 months in the cadonilimab arm vs. 9.5 months in the control arm (HR=0.68), and mOS was not reached in the cadonilimab arm vs. 25.3 months in the control arm (HR=0.69). In patients ≥ 65 years, mPFS was 12 months in the cadonilimab arm vs. 7.4 months in the control arm(HR=0.39), and mOS was 26.6 months in the cadonilimab arm vs. 15.1 months in the control arm (HR=0.49). Cadonilimab Combined with Platinum Agents (Cisplatin/Carboplatin) Improves PFS and OS: In the cisplatin arm, mPFS was 14.7 months in the cadonilimab arm vs. 8.1 months in the control arm (HR=0.49), and mOS was not reached in the cadonilimab arm vs. 23.9 months in the control arm (HR=0.43). In the carboplatin arm, mPFS was 12 months in the cadonilimab arm vs. 8.2 months in the control arm (HR=0.72), and mOS was 27.8 months in the cadonilimab arm vs. 22.8 months in the control arm (HR=0.82). In June 2022, cadonilimab was granted approval by the China National Medical Products Administration (NMPA) for the treatment of recurrent or metastatic cervical cancer in patients who had previously failed platinum-based chemotherapy. This indication has since been included in the national reimbursement list. In September 2024, the use of cadonilimab in first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma was approved by the NMPA. The use of cadonilimab in first-line treatment for advanced, recurrent, or metastatic cervical cancer was approved by the NMPA in May 2025. In addition, cadonilimab is currently being evaluated in nearly 30 registrational/Phase III and Phase II clinical trials across a number of high-incidence cancers. Preliminary results show that cadonilimab demonstrates clinical benefit for patient populationsin both the positive and the negative PD-L1 expression groups, marking a significant advancement over existing immunotherapies. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. ( "Akeso") contains "forward-looking statements" . These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. View original content: SOURCE Akeso, Inc. Sign in to access your portfolio
